Jaguar Health Inc (JAGX) Stock Analysis
Verdict: AVOID
Extreme liquidity depletion and persistent net losses expose JAGX to imminent dilution risk, driving a -74.14% crash toward its $3.21 target.
Investment score: 10/100
Analysis as of
Is Jaguar Health Inc stock worth reviewing? The TradeMates thesis
The model views JAGX as an uninvestable microcap due to near-zero cash runway ($0.97M USD), negative equity (-$17.29M USD), and high debt ($43.61M USD). Following a -74.14% single-day crash to $8.91 USD, further dilution appears imminent.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Jaguar Health Inc opportunities and risks
What speaks for JAGX
- FDA expansion trials for crofelemer in cancer therapy-related diarrhea
What speaks against JAGX
- Existential liquidity deficit and imminent share dilution
Frequently asked questions about Jaguar Health Inc (JAGX)
Is JAGX stock a good investment?
The TradeMates model rates Jaguar Health Inc as AVOID with an investment score of 10/100. The model views JAGX as an uninvestable microcap due to near-zero cash runway ($0.97M USD), negative equity (-$17.29M USD), and high debt ($43.61M USD). Following a -74.14% single-day crash to $8.91 USD, further dilution appears imminent. This is algorithmic model output, not personal investment advice.
Is JAGX stock a buy?
The TradeMates model verdict for JAGX is AVOID with an investment score of 10/100. Treat this as a model signal to review, not a personal buy recommendation.